Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

  title={Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials},
  author={Peter M. Rothwell and F. Gerald R. Fowkes and Jill J.F. Belch and Hisao Ogawa and Charles P. Warlow and Tom W Meade},
  journal={The Lancet},

Figures and Tables from this paper

Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women
Conurrent evaluation of the absolute effects on cancer, CVD and major gastrointestinal bleeding showed that alternate-day use of low-dose aspirin is ineffective or harmful in the majority of women in primary prevention, but selective treatment of women ≥65 years with aspirin may improve net benefit.
Daily aspirin use and cancer mortality in a large US cohort.
Results are consistent with an association between recent daily aspirin use and modestly lower cancer mortality but suggest that any reduction in cancer mortality may be smaller than that observed with long-term aspirin use in the pooled trial analysis.


Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial
Results from this large-scale, long-term trial suggest that alternate day use of low-dose aspirin for an average 10 years of treatment does not lower risk of total, breast, colorectal, or other site-specific cancers.
Eff ect of aspirin on long-term risk of colorectal cancer : consistent evidence from randomised and observational studies
Aspirin has been shown to reduce experimentally-induced colonic malignancies in animals, and some observational studies have reported a reduced incidence of colorectal cancers in regular users of aspirin, although there is substantial heterogeneity in apparent heterogeneity between studies.
Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular Risk
Aspirin treatment for primary prevention is cost-effective for men with a 10-year cardiovascular disease risk of >10% and for women with a risk of>15%, which occurs much later in life for women than men.
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.
In this study of patients with type 2 diabetes, low-dose aspirin as primary prevention did not reduce the risk of cardiovascular events.
Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
Aspirin is effective for the prevention of colorectal adenomas in individuals with a history of these lesions and no statistically significant effect modification for any of the baseline factors studied.